Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc., 6633 [2014-02202]

Download as PDF 6633 Federal Register / Vol. 79, No. 23 / Tuesday, February 4, 2014 / Notices is granted registration as an importer of the basic classes of controlled substances listed. Dated: January 15, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–02209 Filed 2–3–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application; Sigma Aldrich Research Biochemicals, Inc. Pursuant to 21 CFR 1301.33(a), this is notice that on November 19, 2013, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following classes of controlled substances: mstockstill on DSK4VPTVN1PROD with NOTICES Drug Schedule Cathinone (1235) .......................... Etorphine HCl (9059) ................... Methcathinone (1237) .................. Mephedrone(4-Methyl-Nmethylcathinone) (1248). Aminorex (1585) ........................... Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 4-Methyl-2,5dimethoxyamphetamine (7395). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). Dimethyltryptamine (7435) ........... Psilocybin (7437) .......................... 5-Methoxy-N,Ndiisopropyltryptamine (7439). 1-[1-(2-Thienyl)cyclohexyl] piperidine (TCP) (7470). N-Benzylpiperazine (BZP) (7493) MDPV(3,4Methylenedioxypyrovalerone) (7535). VerDate Mar<15>2010 20:14 Feb 03, 2014 I II I I I I I I I I I Drug Schedule Methylone(3,4-Methylenedioxy-Nmethylcathinone) (7540). Heroin (9200) ............................... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Nabilone (7379) ............................ 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Ecgonine (9180) ........................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Meperidine (9230) ........................ Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Remifentanil (9739) ...................... Sufentanil (9740) .......................... Carfentanil (9743) ......................... Fentanyl (9801) ............................ I I I II II II II II II II II II II II II II II II II II II II II The company plans to manufacture reference standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 7, 2014. Dated: January 15, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–02202 Filed 2–3–14; 8:45 am] BILLING CODE 4410–09–P I I DEPARTMENT OF JUSTICE I Drug Enforcement Administration I I I I I I I I Jkt 232001 Manufacturer of Controlled Substances; Notice of Application; Johnson Matthey Pharmaceutical Materials, Inc. Pursuant to 21 CFR 1301.33(a), this is notice that on December 23, 2013, Johnson Matthey Pharmaceutical Materials, Inc., Pharmaceutical Service, 25 Patton Road, Devens, Massachusetts 01434, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: PO 00000 Frm 00103 Fmt 4703 Sfmt 4703 Drug Amphetamine (1100) .................... Methylphenidate (1724) ................ Nabilone (7379) ............................ Hydrocodone (9193) ..................... Alfentanil (9737) ........................... Remifentanil (9739) ...................... Sufentanil (9740) .......................... Schedule II II II II II II II The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODW), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 7, 2014. Dated: January 15, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2014–02208 Filed 2–3–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cambridge Isotope Lab By Notice dated August 15, 2013, and published in the Federal Register on August 26, 2013, 78 FR 52802, Cambridge Isotope Lab, 50 Frontage Road, Andover, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedule II. The company plans to utilize small quantities of the listed controlled substance in the preparation of analytical standards. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of E:\FR\FM\04FEN1.SGM 04FEN1

Agencies

[Federal Register Volume 79, Number 23 (Tuesday, February 4, 2014)]
[Notices]
[Page 6633]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-02202]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application; 
Sigma Aldrich Research Biochemicals, Inc.

    Pursuant to 21 CFR 1301.33(a), this is notice that on November 19, 
2013, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, 
Natick, Massachusetts 01760-2447, made application by renewal to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Etorphine HCl (9059).......................  II
Methcathinone (1237).......................  I
Mephedrone(4-Methyl-N-methylcathinone)       I
 (1248).
Aminorex (1585)............................  I
Alpha-ethyltryptamine (7249)...............  I
Lysergic acid diethylamide (7315)..........  I
Tetrahydrocannabinols (7370)...............  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
3,4-Methylenedioxyamphetamine (7400).......  I
N-Hydroxy-3,4-methylenedioxyamphetamine      I
 (7402).
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (MDMA)     I
 (7405).
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
5-Methoxy-N,N-diisopropyltryptamine (7439).  I
1-[1-(2-Thienyl)cyclohexyl] piperidine       I
 (TCP) (7470).
N-Benzylpiperazine (BZP) (7493)............  I
MDPV(3,4-Methylenedioxypyrovalerone) (7535)  I
Methylone(3,4-Methylenedioxy-N-              I
 methylcathinone) (7540).
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Nabilone (7379)............................  II
1-Phenylcyclohexylamine (7460).............  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Ecgonine (9180)............................  II
Levomethorphan (9210)......................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Metazocine (9240)..........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Levo-alphacetylmethadol (9648).............  II
Remifentanil (9739)........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODW), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than April 7, 2014.

    Dated: January 15, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2014-02202 Filed 2-3-14; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.